Phase 3 Shock: Novo Nordisk’s CagriSema Loses to Eli Lilly’s Tirzepatide
2026-02-28I. Market Insight: The New Standard of EfficacyOn February 23, 2026, Novo Nordisk released the REDEFINE 4 Phase 3 results—a head-to-head trial to challenge Eli Lilly’s GLP-1 market dominance. Data ...
Pfizer-Xianweida Collaboration Ignites GLP-1 API Boom: Guizhou Utide’s Customer Cases Reveal Its Core Strength
2026-02-28 Recently, a major collaboration between Pfizer and Xianweida has become a hot topic in the global pharmaceutical industry — the two parties have joined hands to promote the commercializatio...
The Hidden War Behind the Pharmaceutical King's Succession: How a $36.5 Billion Order Tests the Global Supply Chain
2026-02-28Ⅰ. A historic shiftIn 2025, the global pharmaceutical industrysaw a historic shift: Eli Lilly’s tirzepatide narrowlydethroned Novo Nordisk’s semaglutide as the new"King of Pharmaceuticals" with $36...
Eli Lilly’s GLP-1 Therapy Breakthrough:Global Peptide API Demand Surges, Highlighting UTIDE’s Guizhou Manufacturing& HK Commercial Capabilities
2026-02-281. Hot Spot Cut-In: Eli Lilly’s Trial Boosts GLP-1 Peptide API DemandOn January 8, 2026, Eli Lilly and Company announced positive top-line results from its Phase IIIb TOGETHER-PsA study, evaluating...
Starbucks Menu Overhaul: Viral High-Protein, Small-Portion Options Reveal Hidden Shifts in GLP-1 Supply Chain
2026-02-28 Seattle, USA — A pivotal shift from café menus to core manufacturing is underway, as global coffee giant Starbucks takes the lead in adapting to GLP-1-driven dietary changes by launching and expan...
Utide Honored with National Peptide Industry Award for Scalable Production
2026-02-03Utide Honored with National Peptide Industry Award for Scalable ProductionThe 11th National Conference on Peptide Drug R&D and Large-Scale Production Frontier Technology successfully convened in Sa...
Breaking News: Guizhou Utide Biotechnology’s Tirzepatide and Retatrutide Successfully Pass U.S. Drug Master File (DMF) Filing for Peptide Active Pharmaceutical Ingredients!
2026-01-30Breaking News: Guizhou Utide Biotechnology’s Tirzepatide and Retatrutide Successfully Pass U.S. Drug Master File (DMF) Filing for Peptide Active Pharmaceutical Ingredients!Recently, the U.S. Food a...
Address
Standardized Factory Building 7, 4th Floor, Pharmaceutical Product Trading Center, Shenxi Town，Honghuagang District, Zunyi City,Guizhou Province
1603-1, Wanxia Center,Tower C, Phase ll of Haijingjie Jiayuan, No. 27, Zhaoshang EastRoad, Dongjiaotou Community，Shekou Sub-district, Nanshan District，Shenzhen City, Guangdong Province,China
Utidechem